New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
Miguel A. Chávez-Fumagalli,Tatiana G. Ribeiro,Rachel Oliveira Castilho,Simone Odília Antunes Fernandes,Valbert Nascimento Cardoso,Cecília Steinberg Perilo Coelho,Débora V.C. Mendonça,Manuel Soto,Carlos Alberto Pereira Tavares,André Augusto Gomes Faraco,Eduardo A.F. Coelho +10 more
TLDR
These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.Abstract:
Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.read more
Citations
More filters
Anti-inflammatory activity on chondroitin sulfate
TL;DR: In rats the oral administration of CS significantly decreases granuloma formation due to sponge implants and cell migration and lysosomal enzyme release in carrageenan pleurisy and compared with nonsteroidal anti-inflammatory drugs, CS appears to be more effective on cellular events of inflammation than on edema formation.
Journal ArticleDOI
Application of nanotechnology in treatment of leishmaniasis: A Review.
TL;DR: This study attempts to present a comprehensive overview of different approaches of nanotechnology in treatment of leishmaniasis as well as new drug delivery devices transport antileishmanial drug to the target cell specifically with minimizing the toxic effects to normal cells.
Journal ArticleDOI
Leishmaniasis treatment: update of possibilities for drug repurposing.
Valter Viana Andrade-Neto,Edézio Ferreira Cunha-Júnior,Dos Santos Faioes,Thaís Martins Pereira,Silva Rl,Leonor L. Leon,Eduardo Caio Torres-Santos +6 more
TL;DR: In this paper, a broad analysis of the different aspects of this approach for anti-leishmanial treatment is presented, as well as a broad review of the use of drugs that are already used for other diseases.
Journal ArticleDOI
Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
Mariana C. Duarte,Daniela P. Lage,Vívian T. Martins,Miguel A. Chávez-Fumagalli,Bruno Mendes Roatt,Daniel Menezes-Souza,Luiz Ricardo Goulart,Luiz Ricardo Goulart,Manuel Soto,Carlos Alberto Pereira Tavares,Eduardo A.F. Coelho +10 more
TL;DR: Recent advances in control measures for VL based on vaccine development are presented, describing extensively studied antigens, as well as new antigenic proteins recently identified using immuno-proteomic techniques.
Journal ArticleDOI
Nanoparticles: New agents toward treatment of leishmaniasis.
Amir Hossein Nafari,Koroush Cheraghipour,Maryam Sepahvand,Ghazal Shahrokhi,Esraa Gabal,Hossein Mahmoudvand +5 more
TL;DR: The review of nanoparticles as a new method in leishmaniasis treatment indicates that incorporating nanoparticles with chemical drugs improves the quality, efficiency, and sustainability of drugs and reduces their costs.
References
More filters
Journal ArticleDOI
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Jorge Alvar,Iván D. Vélez,Iván D. Vélez,Caryn Bern,Mercè Herrero,Philippe Desjeux,Jorge Cano,Jean Jannin,Margriet den Boer +8 more
TL;DR: Visceral and cutaneous leishmaniasis incidence ranges were estimated by country and epidemiological region based on reported incidence, underreporting rates if available, and the judgment of national and international experts.
Journal ArticleDOI
Leishmaniasis: current situation and new perspectives.
TL;DR: Research for leishmaniasis has been more and more focusing on the development of new tools such as diagnostic tests, drugs and vaccines, and the newly available control tools should allow a scaling up of control activities in priority areas.
Journal ArticleDOI
Chitosan-based hydrogels for controlled, localized drug delivery
TL;DR: The newest developments in chitosan hydrogel preparation are investigated and the design parameters in the development of physically and chemically cross-linked hydrogels are defined.
Journal ArticleDOI
Principles of early drug discovery
TL;DR: This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.
Journal ArticleDOI
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
François Chappuis,François Chappuis,Shyam Sundar,Asrat Hailu,H. W. Ghalib,Suman Rijal,Rosanna W. Peeling,Jorge Alvar,Marleen Boelaert +8 more
TL;DR: Millefosine, paromomycin and liposomal amphotericin B are gradually replacing pentavalent antimonials and conventional amphoteric in B as the preferred treatments in some regions, but in other areas these drugs are still being evaluated in both mono- and combination therapies.
Related Papers (5)
Leishmaniases of the New World: current concepts and implications for future research.
Gabriel Grimaldi,Robert B. Tesh +1 more
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Simon L. Croft,Graham H. Coombs +1 more
Antigenicity and Protective Efficacy of a Leishmania Amastigote-specific Protein, Member of the Super-oxygenase Family, against Visceral Leishmaniasis
Vívian T. Martins,Miguel A. Chávez-Fumagalli,Lourena E. Costa,Adriana Monte Cassiano Canavaci Martins,Paula S. Lage,Daniela P. Lage,Mariana C. Duarte,Diogo G. Valadares,Rubens Daniel Miserani Magalhães,Tatiana G. Ribeiro,Ronaldo Alves Pinto Nagem,Wanderson D. DaRocha,Wiliam César Bento Régis,Manuel Soto,Eduardo A.F. Coelho,Ana Paula Fernandes,Carlos Alberto Pereira Tavares +16 more